Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo, Keith W. Pratz, Vinod Pullarkat, Brian A. Jonas, Martha Arellano, Pamela S. Becker, Olga Frankfurt, Marina Konopleva, Andrew H. Wei, Hagop M. Kantarjian, Tu Xu, Wan-Jen Hong, Brenda Chyla, Jalaja Potluri, Daniel A. Pollyea, Anthony Letai
Blood, 2018
Abstract
This research paper explore the methodology and findings associated with Blood. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).
- Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism 2021
- Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings 2016
- Venetoclax with decitabine or azacitidine for AML 2018
- Practical Recommendations for Hypomethylating Agent Therapy of Patients With Myelodysplastic Syndromes 2010
- The euphoria of hypomethylating agents in MDS and AML: Is it justified? 2013
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts 2015
- Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: 2006
- Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells 2012
- MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia 2004
- Treatment of FLT3-ITD acute myeloid leukemia. 2011